前列腺特异性抗原筛查模式对非西班牙裔黑人与非西班牙裔白人男性前列腺癌死亡率的影响:一项大型城市卫生系统队列分析
该研究纳入6378例在本机构接受PSA筛查并确诊前列腺癌的男性,按确诊前5年PSA检测强度分为从未、部分(<1次/年)和每年检测(1次/年)三组,评估前列腺癌特异性死亡率(PCSM)。结果显示PSA筛查率与更有利的PCSM相关(HR 0.47,95%CI 0.33-0.68,P<.001),且种族交互项无统计学显著性(P=.2),提示筛查率的正向影响似乎独立于种族。
要点
- 每年PSA检测在非西班牙裔白人男性中比非西班牙裔黑人男性更常见(5% vs 3%,χ2 P<.001)。
- 10年PCSM在从未、部分、每年PSA检测组中,非西班牙裔白人分别为12.3%、5.8%、4.6%,非西班牙裔黑人分别为18.5%、7%、1.2%(Gray检验P<.001)。
- PSA筛查率与更有利的PCSM相关(HR 0.47,95%CI 0.33-0.68,P<.001),种族交互项无统计学显著性(P=.2)。
核心结论
- PSA检测与确诊前列腺癌的非西班牙裔黑人和非西班牙裔白人男性中PCSM风险降低相关。
- 此外,筛查率的正向影响似乎独立于种族。
研究设计与样本
- 研究队列纳入6378例自我认同为非西班牙裔黑人或非西班牙裔白人、并确诊前列腺癌的男性。
- 患者在本机构接受PSA筛查及后续前列腺癌治疗和随访。
- 按确诊前5年PSA检测强度分为从未、部分(<1次/年)和每年检测(1次/年)三组。
- 主要结局为前列腺癌特异性死亡率(PCSM)风险,采用竞争风险累积发生率曲线和竞争风险回归分析。
主要发现
- 诊断时中位(IQR)年龄和PSA分别为67(60-73)岁和5.8(4.4-9.6)ng/mL,其中2929(46%)例为非西班牙裔黑人(Kruskal-Wallis P值<.001)。
- 每年PSA检测在非西班牙裔白人男性中比非西班牙裔黑人男性更常见(5% vs 3%,χ2 P值<.001)。
- 在从未、部分和每年PSA检测组中,10年PCSM在非西班牙裔白人分别为12.3%、5.8%和4.6%,在非西班牙裔黑人分别为18.5%、7%和1.2%(Gray检验P值<.001)。
- 竞争风险回归显示,PSA筛查率与更有利的PCSM率相关(HR 0.47,95%CI 0.33-0.68,P<.001)。
- 种族交互项未显示统计学显著性(P=.2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Randomized studies assessing the effect of PSA screening on mortality in non-Hispanic Black (NHB) men are lacking. We aimed to assess the association between PSA screening and survival among NHB men in comparison to non-Hispanic White (NHW) men in a racially diverse real-world North American population. MATERIALS AND METHODS: The study cohort included 6378 men who self-identified as NHB or NHW and were diagnosed with prostate cancer (PCa). Patients received PSA screening and subsequent PCa treatment and follow-up at our institution. Patients were sorted based on PSA testing intensity for the 5 years prior to diagnosis, as follows: never, some (<1 test/y), and annual testing (1 test/y). The primary outcome was risk of prostate cancer-specific mortality (PCSM). Competing risk cumulative incidence curves estimated PCSM rates. Competing risk regression analyses examined the impact of PSA testing on PCSM. An interaction term was incorporated to assess the impact of race on the outcome. RESULTS: Median (IQR) age and PSA at diagnosis were 67 (60-73) years and 5.8 (4.4-9.6) ng/mL, respectively, and 2929 (46%) men were NHB (Kruskal-Wallis P values < .001). Annual PSA testing was more frequent in NHW (5%) than in NHB (3%) men (χ2 P value < .001). On cumulative incidence analysis, in the never, some, and annual PSA testing groups, the 10-year PCSM was respectively 12.3%, 5.8%, and 4.6% in NHW and 18.5%, 7%, and 1.2% in NHB patients (Gray's test P values < .001). At competing risk regression, PSA screening rate was associated with more favorable PCSM rates (HR: 0.47; 95% CI 0.33-0.68; P < .001). The interaction term for race did not show statistical significance (P = .2). CONCLUSIONS: PSA testing was associated with a reduced risk of PCSM in both NHB and NHW men diagnosed with PCa. Additionally, the positive impact of the screening rate seemed to be independent of race.
引用
- Cirulli GO, Davis M, Stephens A, et al. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis. J Urol. 2024. PMID: 39079152. doi:10.1097/JU.0000000000004118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。